Mounjaro: What It Is, How It Works, and Uses

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub, covering the practical questions behind the tirzepatide-and-Mounjaro search: what the brand is, how it works, what it treats, its side effects, and the cost picture. Browse all Peptides & GLP-1 education.

What Mounjaro is

Mounjaro is Eli Lilly's brand of tirzepatide, a GIP/GLP-1 dual agonist. The FDA has approved tirzepatide for type 2 diabetes under the Mounjaro name, for chronic weight management under the Zepbound name, and for obstructive sleep apnea in adults with obesity under Zepbound in 2024. The distinguishing feature of this molecule is its GIP and GLP-1 dual mechanism, which sets it apart from single-target agonists.

Why one molecule wears two brand names

A frequent point of confusion is that Mounjaro and Zepbound share the same underlying molecule, tirzepatide, yet carry different names. The reason is regulatory: each brand is approved for a different set of indications, with Mounjaro tied to type 2 diabetes and Zepbound tied to chronic weight management and obstructive sleep apnea. That branding distinction has real consequences. Because prescribing follows the brand's approved indication, the same molecule under a different name is not automatically interchangeable for insurance or coverage purposes, and a prescriber matches the brand to the indication being treated. Understanding that a single active ingredient can appear under two names, governed by two labels, clears up much of the confusion these searches tend to generate.

How it works

GLP-1 receptor agonists engage the GLP-1 receptor across the pancreas, hypothalamus, and gastrointestinal tract, slowing gastric emptying, blunting post-meal glucose excursions, reducing appetite, and increasing satiety signaling. As a GIP/GLP-1 dual agonist, tirzepatide additionally engages the GIP receptor, adding a second incretin mechanism. Weekly or daily dosing, depending on the compound, delivers sustained receptor engagement over time, which is part of why the class is administered on a schedule rather than only around meals.

What it is used for

Across this class, the FDA-approved indications include type 2 diabetes for most compounds, chronic weight management for products such as Wegovy, Saxenda, and Zepbound, cardiovascular risk reduction in type 2 diabetes for several products, and obstructive sleep apnea in adults with obesity for Zepbound in 2024. Prescribing follows each brand's approved indication, and the same molecule under a different brand is not automatically interchangeable for insurance or coverage.

Common side effects

Gastrointestinal symptoms, namely nausea, vomiting, diarrhea, and constipation, are reported most often and tend to be most pronounced during dose titration. Every FDA-approved GLP-1 compound carries the class boxed warning for thyroid C-cell tumor risk observed in rodent studies. Rare serious events include pancreatitis, gallbladder disease, and acute kidney injury in the context of dehydration. Because these effects are shared across the GLP-1 class rather than unique to one brand, the safety framework a provider applies to Mounjaro looks much like the one applied to any compound in this category.

Cost and access

Manufacturer list prices for FDA-approved branded products generally run from $800 to $1,600 per month at U.S. list as of April 2026. Actual out-of-pocket cost depends on insurance coverage, the FDA indication on the prescription, savings-card eligibility, and whether a compounded alternative is available through a licensed 503A pharmacy pathway. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, including Tirzepatide Injection and Tirzepatide Oral.

The genetic context beneath the brand

Understanding your baseline biology adds depth to any decision about a metabolic protocol. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including variants in FTO and MC4R, and TCF7L2 that shape appetite regulation, energy balance, and baseline GLP-1 signaling. These are trait-level insights, not a forecast of drug response, and the panel is not pharmacogenomic. It maps the metabolic terrain a clinician is prescribing into.

Frequently Asked Questions

What is Mounjaro?

Mounjaro is Eli Lilly's brand of tirzepatide, a GIP/GLP-1 dual agonist FDA-approved for specific indications including type 2 diabetes, with the tirzepatide molecule also approved as Zepbound for chronic weight management and obstructive sleep apnea. It engages the GLP-1 pathway to modulate appetite, satiety, and glucose regulation, administered per the product label.

How does Mounjaro work?

Mounjaro engages the GLP-1 receptor and, as tirzepatide, the GIP receptor, slowing gastric emptying, blunting post-meal glucose excursions, reducing appetite, and increasing satiety signaling. Weekly dosing delivers sustained receptor engagement. Effects on weight and A1C vary by compound and dose according to clinical trial data and individual factors.

What is Mounjaro used for?

Mounjaro is FDA-approved for specific indications per its label. Some GLP-1 products are approved for type 2 diabetes, others for chronic weight management, and Zepbound is additionally approved for obstructive sleep apnea in adults with obesity in 2024. Your prescribing provider matches the brand to the appropriate indication for your situation.

How does the Precision Peptide Genetic Test relate to my GLP-1 pathway?

It does not predict response to Mounjaro or any medication. It analyzes pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology, offering the upstream context that applies across every GLP-1 pathway compound rather than a drug-specific result.

Start with the biology underneath the brand. Take the Precision Peptide Genetic Test, then talk options over with your provider. Return to the Education Hub.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.